heart failure with reduced ejection fraction
Cardiovascular · 2016–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| eplerenone Chronic heart failure with left ventricular ejection fraction ≤40%, either within 3–14 days of acute myocardial infarction or as NYHA class II–IV symptomatic… | Jul 2025 | Recommended with restriction | input received |
| dapagliflozin Treatment of patients with symptomatic heart failure with reduced ejection fraction (HFrEF) who are receiving concomitant optimal standard chronic heart… | Jul 2021 | Deferred | input received Diabetes Australia · National Aboriginal Community Controlled Health Organisation |
| dapagliflozin Treatment of patients with symptomatic chronic heart failure with reduced ejection fraction (NYHA class II-IV) receiving optimal standard care (ACE inhibitor,… | Nov 2020 | Not recommended | none received |
| sacubitril/valsartan Treatment of chronic heart failure with reduced ejection fraction (LVEF <50%), NYHA Class II-IV, with or without prior stabilisation on ACE-inhibitors or ARBs. | Nov 2020 | Not recommended | none received |
| sacubitril with valsartan Treatment of chronic heart failure with reduced ejection fraction (NYHA class II-IV) with left ventricular ejection fraction ≤40%. | Mar 2016 | Not recommended | none received |
Who spoke
Diabetes Australia · National Aboriginal Community Controlled Health Organisation
What the PBS pays
$502M in government benefit over 2024–25, across 7,559,666 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| sacubitril with valsartan | $191.3M |
| sacubitril/valsartan | $191.3M |
| dapagliflozin | $114.2M |
| eplerenone | $4.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| empagliflozinEmpagliflozin for treating chronic heart failure with reduced ejection fraction | TA773 | recommended restricted | 2022-03 |
| vericiguatVericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) | TA731 | terminated | 2021-09 |
| dapagliflozinDapagliflozin for treating chronic heart failure with reduced ejection fraction | TA679 | recommended restricted | 2021-02 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.